Zacks: Analysts Expect Becton, Dickinson and Company (NYSE:BDX) Will Announce Quarterly Sales of $4.46 Billion

Equities research analysts expect Becton, Dickinson and Company (NYSE:BDXGet Rating) to post $4.46 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Becton, Dickinson and’s earnings, with estimates ranging from $4.40 billion to $4.52 billion. Becton, Dickinson and posted sales of $4.89 billion in the same quarter last year, which would indicate a negative year-over-year growth rate of 8.8%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Becton, Dickinson and will report full-year sales of $18.62 billion for the current financial year, with estimates ranging from $18.60 billion to $18.65 billion. For the next financial year, analysts forecast that the firm will post sales of $19.42 billion, with estimates ranging from $19.25 billion to $19.67 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.20. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The business had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. During the same period last year, the company earned $3.19 earnings per share. Becton, Dickinson and’s quarterly revenue was up 2.1% compared to the same quarter last year.

BDX has been the topic of several analyst reports. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Friday, April 1st. SVB Leerink raised their price target on Becton, Dickinson and from $270.00 to $275.00 and gave the company a “market perform” rating in a research report on Friday, February 4th. Morgan Stanley raised their price target on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research report on Monday, April 11th. Bank of America initiated coverage on Becton, Dickinson and in a research report on Tuesday, March 1st. They issued a “neutral” rating on the stock. Finally, Argus raised their price target on Becton, Dickinson and from $275.00 to $310.00 in a research report on Monday, February 28th. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and has an average rating of “Hold” and a consensus target price of $275.63.

In related news, EVP Betty D. Larson sold 14,374 shares of the business’s stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Hickey sold 475 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $256.00, for a total transaction of $121,600.00. Following the completion of the transaction, the executive vice president now owns 3,806 shares of the company’s stock, valued at approximately $974,336. The disclosure for this sale can be found here. Insiders own 0.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Becton, Dickinson and by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 24,487,340 shares of the medical instruments supplier’s stock worth $6,513,633,000 after acquiring an additional 310,974 shares during the period. BlackRock Inc. grew its holdings in shares of Becton, Dickinson and by 4.2% in the 4th quarter. BlackRock Inc. now owns 20,694,679 shares of the medical instruments supplier’s stock valued at $5,204,300,000 after buying an additional 828,789 shares during the period. Wellington Management Group LLP grew its holdings in shares of Becton, Dickinson and by 6.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,489,749 shares of the medical instruments supplier’s stock valued at $3,561,871,000 after buying an additional 837,802 shares during the period. State Street Corp grew its holdings in shares of Becton, Dickinson and by 3.9% in the 4th quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock valued at $3,195,105,000 after buying an additional 480,684 shares during the period. Finally, Morgan Stanley grew its holdings in shares of Becton, Dickinson and by 7.1% in the 3rd quarter. Morgan Stanley now owns 9,827,875 shares of the medical instruments supplier’s stock valued at $2,415,888,000 after buying an additional 652,875 shares during the period. Hedge funds and other institutional investors own 86.58% of the company’s stock.

Becton, Dickinson and stock opened at $252.30 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The company has a market capitalization of $71.92 billion, a price-to-earnings ratio of 39.79, a PEG ratio of 4.15 and a beta of 0.64. Becton, Dickinson and has a one year low of $235.13 and a one year high of $280.62. The company’s fifty day moving average price is $260.32 and its two-hundred day moving average price is $257.81.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be paid a $0.87 dividend. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.38%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 54.89%.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

See Also

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.